




AAV production in suspension system

FectoVIR®-AAV

- High performance: Superior yields for rAAV production
- Scalability: Developed for small to large scale production
- Flexibility: Compatible with commercial culture media
- Trustworthy: #1 supplier of gene and cell therapy
- **GMP compliance: GMP grade coming soon**

FectoVIR®-AAV outperforms its main competitors for AAV production in suspension cells:




rAAV-2 were produced in suspension HEK-293T cells and harvested 72h post-transfection.


FectoVIR®-AAV allows a flexible process for small to large scale suspension cell systems:

Optimized to reduce complexation volume down to 1%, enabling larger transfection volumes.

Longer stability of transfection complexes, allowing more time to work with larger volumes / to add larger volumes to cells.



rAAV-2 were produced in suspension HEK-293T cells and harvested 72h posttransfection.



rAAV-2 were produced in suspension HEK-293T cells and harvested 72h post-transfection

120-100

10 ml

100 ml

Product Reagent size 120-001 **Contact us:** FectoVIR®-AAV 120-010 www.polyplus-transfection.com

+33 (0)3 90 40 61 80 support@polyplus-transfection.com